GHK-Cu research: identity, studies and evidence limits
Evidence summary: GHK is the tripeptide glycyl-L-histidyl-L-lysine; GHK-Cu is its copper(II) complex. Published evidence includes in-vitro and animal work plus older topical wound studies. It does not establish injectable efficacy or safety, and topical formulation findings cannot be transferred to a laboratory vial.
Key findings
- Free GHK and copper-complexed GHK-Cu are different analytical identities.
- The strongest human evidence is route- and formulation-specific topical wound research.
- No published human randomized trial validates injectable GHK-Cu.
Identity comes before interpretation
A report should specify whether it characterizes free GHK or the copper complex, along with the expected molecular species, counterion basis and lot. A mass value for free GHK should not be presented as the molecular weight of GHK-Cu.
HPLC can describe chromatographic purity and LC-MS can support identity. Neither alone measures copper stoichiometry; elemental or suitable spectroscopic analysis answers that separate question.
What preclinical studies suggest
Cell, tissue and animal studies summarized in the peer-reviewed literature examine fibroblast signaling, extracellular-matrix remodeling, oxidative stress and wound models. These are mechanistic or preclinical observations, not proof of a clinical outcome.
Much of the broad gene-expression narrative comes from reviews by researchers closely associated with GHK-Cu development. That literature is useful for hypotheses but needs independent replication and endpoint-specific interpretation.
What human topical evidence shows
A 1994 randomized study of topical GHK-Cu gel in diabetic ulcers reported a benefit in an immediate-treatment plantar-ulcer subgroup, while other arms were not superior to vehicle. An earlier venous-ulcer trial reported no benefit over vehicle.
These studies concern topical formulations in defined wound populations. They do not support extrapolation to injection, systemic exposure, cosmetic products generally or PeptidesDirect laboratory material.
Analytical questions for a GHK-Cu lot
Confirm the named complex, lot, expected mass basis, chromatographic method and whether copper content was actually measured. Color or a QR code is not identity evidence.
Where a PeptidesDirect report is available, match it to the product and lot. Missing tests remain unconfirmed rather than inferred from a supplier-wide claim.
Continue to the full evidence guide
Frequently asked questions
Is GHK-Cu the same as GHK?
No. GHK is the free tripeptide; GHK-Cu is its copper complex.
Is there human evidence for injectable GHK-Cu?
No published randomized human trial validating injectable GHK-Cu was identified.
Does HPLC prove copper content?
No. HPLC purity and copper content are separate analytical questions.
Primary references
- Pickart L, Vasquez-Soltero JM. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015. PubMed 26236730
- Mulder GD, et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-L-histidyl-L-lysine copper. Wound Repair Regen. 1994. PubMed 17147644
- Boyne MT, et al. Liquid Chromatography-High Resolution Mass Spectrometry for Peptide Drug Quality Control. AAPS J. 2015. PubMed 25716148
Related research materials
Research Use Only. Not for human or veterinary use. This page is not dosing or medical guidance.
